Open AccessBortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy
Author(s) -
Abdallah S. Geara,
Vijay Bhoj,
Jonathan J. Hogan
Publication year - 2021
Publication title -
glomerular diseases
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2673-3633
DOI - 10.1159/000515087
Subject(s) - bortezomib , medicine , rituximab , nephrotic syndrome , cyclophosphamide , membranous nephropathy , antibody , gastroenterology , refractory (planetary science) , b cell , plasma cell , spontaneous remission , immunology , proteinuria , kidney , multiple myeloma , pathology , chemotherapy , biology , alternative medicine , astrobiology
B-cell depletion has been shown to be an effective strategy for the majority of patients with membranous nephropathy (MN), and in PLA2R-positive MN, immunologic remission (improvement or elimination of measurable serum anti-PLA2R antibodies) precedes renal remission. Yet, cases exist of patients who do not achieve immunologic remission despite achieving peripheral B-cell depletion. This has led to the hypothesis that some patients have plasma cells that are responsible for producing anti-PLA2R antibodies.